top of page
Contact Us
Contact Us

More case studies

Ensuring batch-consistent, compliant comparator supply across NA, EU, and APAC - on time and uninterrupted.

Effective Sourcing of Semaglutide for a Global Phase III Clinical Trial

From supply shortfall to on-time first-patient-first-visit across Europe, delivered in three days.

CSI's 72-hour Abraxane Rescue Mission

Adaptive, multi-product supply across 22 countries and 80 sites, kept on time, in budget and compliant.

CSI’s Expert Delivery of a Global Respiratory Study

A leading global biopharmaceutical company urgently requested CSI to supply the Fluarix QIV Southern Hemisphere Vaccine for 2025.

Rapid Sourcing of Discontinued Southern Hemisphere Vaccine for a Global Biopharmaceutical Client

Securing reliable, cost-effective, long-term supply of Eylea PFS from EU and USA for a global biotech company’s clinical studies.

Securing Long-Term, Cost-Effective Supply of Eylea EU & USA for programs of studies

A biotech client asked CSI to source Lucentis for a Phase II ophthalmology trial.

Comparator Sourcing for a Phase II Ophthalmology Study

CSI Efficiently Delivered Venetoclax and Azacitidine Across 17 Countries

How CSI streamlined Venetoclax and Azacitidine supply across 17 countries in record time

Export of expensive comparators from Europe to China with first leg documents and streamlined approach

CSI’s seamless comparator export to China

CSI’s flexible approach to global distribution ensured a large CRO's five-year and three-year studies across a total of 18 countries could proceed without delay

Global Device Distribution

How CSI rescued an oncology trial when a competitor failed to deliver, despite an extremely tight deadline and scarce supply on the market

Rescuing a Global Biotech's Oncology Study with Cetuximab

How CSI fulfilled what our competitors couldn’t: rapidly sourcing oncology medication from the EU for a trial in South Korea

Rescuing a Biotech’s Oncology Trial with Lenvima

How CSI has saved a leading global pharmaceutical company €1 million by sourcing pembrolizumab from the market at the best possible price

Delivering €1 million Savings for Pembrolizumab

Challenge

CSI was approached by a Biotech conducting a full global Phase 3 oncology study spanning 14 countries. We were asked to purchase and supply a significant quantity of ruxolitinib within a tight timeframe: with the contract signed in December 2022, the client aimed to have the first sites supplied by March 2023. The client also required three annual resupplies of the oncology medicine to be factored into the request.

Solution

Within eight weeks, the entire study setup had been meticulously organised, ensuring the smooth and timely execution of the clinical trial supply chain. CSI’s strong relationships with manufacturers around the world and outstanding access to oncology products allowed for the procurement of a substantial volume of ruxolitinib within a short timeframe. CSI’s global depot network facilitated the efficient delivery of the oncology medication without delay – just in time for the client’s tight deadline.

Result

CSI’s scientific expertise ensured a seamless and smart study setup, with all aspects of the trial addressed meticulously in the supply planning phase. Despite the challenge of working to a tight deadline and the logistical complexities involved in coordinating product supply across 14 countries, nine depots and 67 individual site shipments, CSI successfully delivered a large quantity of the required oncology medicine in line with the client’s needs and expectations. This, in turn, allowed for Site Initiation Visits (SIVs), which had already been scheduled, to take place as planned, keeping the client’s study on track.

Case Study

Global Jakavi Study

How CSI supplied large quantities of Jakavi to a Biotech’s ongoing Phase 3 oncology study involving 14 countries, nine depots and 67 site shipments

Challenge

To supply a global Phase 3 oncology study spanning 14 countries within a tight eight-week timeframe and to ensure regular resupply for three years

Solution

CSI’s manufacturer relationships and global depot network ensured a large quantity of ruxolitinib could be procured and delivered precisely when needed

Result

Efficient supply of the required oncology product allowed for scheduled Site Initiation Visits (SIVs) to take place, keeping the client’s study on track

Get in touch with a member of our experienced team today to discuss your clinical trial supply requirements

Contact us 

bottom of page